Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
Luis M. RuilopeRajiv AgarwalStefan D. AnkerGerasimos FilippatosBertram PittPeter RossingPantelis SarafidisRoland E. SchmiederAmer JosephNicole MentenichChristina NowackGeorge L. BakrisCardiorenal Translational Laboratory and Hypertension Unit,Institute of Research imas12,Madrid,Spain (L.M.R.).CIBER-CV,Hospital Universitario 12 de Octubre,Madrid,Spain (L.M.R.).Faculty of Sport Sciences,European University of Madrid,Madrid,Spain (L.M.R.). Richard L. Roudebush VA Medical Center and Indiana University,Indianapolis,IN (R.A.).Department of Cardiology (CVK),and Berlin Institute of Health Center for Regenerative Therapies,German Centre for Cardiovascular Research Partner Site Berlin,Charité Universitätsmedizin,Berlin,Germany (S.D.A.).National and Kapodistrian University of Athens,School of Medicine,Department of Cardiology,Attikon University Hospital,Athens,Greece (G.F.).Department of Medicine,University of Michigan School of Medicine,Ann Arbor (B.P.).Steno Diabetes Center Copenhagen,Herlev,Denmark (P.R.).Department of Clinical Medicine,University of Copenhagen,Denmark (P.R.).Department of Nephrology,Hippokration Hospital,Aristotle University of Thessaloniki,Greece (P.S.).Department of Nephrology and Hypertension,University Hospital Erlangen,Germany (R.E.S.).Cardiology and Nephrology Clinical Development,Bayer AG,Berlin,Germany (A.J.).Statistics and Data Insights,Bayer AG,Wuppertal,Germany (N.M.).Research and Development,Clinical Development Operations,Bayer AG,Wuppertal,Germany (C.N.).Department of Medicine,University of Chicago Medicine,IL (G.L.B.).
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.19744
IF: 9.8968
2022-10-13
Hypertension
Abstract:Chronic kidney disease is frequently associated with hypertension and poorly controlled blood pressure can lead to chronic kidney disease progression. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, significantly improves cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes. This analysis explored the relationship between office systolic blood pressure (SBP) and cardiorenal outcomes with finerenone in FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease). Patients with type 2 diabetes, urine albumin-to-creatinine ratio 30 to 5000 mg/g, and estimated glomerular filtration rate of 25 to 148 mm Hg. Overall, patients with lower baseline office SBP quartile and greater declines from baseline in SBP were associated with better cardiorenal outcomes. The risk of primary kidney and key secondary cardiovascular composite outcomes was consistently reduced with finerenone versus placebo irrespective of baseline office SBP quartiles ( P value for interaction 0.87 and 0.78, respectively). A time-varying analysis revealed that 13.8% and 12.6% of the treatment effect with finerenone was attributed to the change in office SBP for the primary kidney composite outcome and the key secondary cardiovascular outcome, respectively. In FIDELIO-DKD, cardiorenal outcomes improved with finerenone irrespective of baseline office SBP. Reductions in office SBP accounted for a small proportion of the treatment effect on cardiorenal outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02540993.
peripheral vascular disease